Research and


CONFO® body-enabled drug discovery‚Äč

Confo Therapeutics has the proprietary technology to lock targets in their disease-linked, druggable conformation for hit identification and optimization. This forms the basis of the very sensitive Confobody-enabled screening method (CONFO® screen), which identifies differentiating chemical series with the appropriate therapeutic mode of action. Such conformation-biased ligands selectively engage only a subset of the receptor's intracellular signaling partners and will deliver superior therapeutic benefit with fewer side effects than current GPCR-targeted drugs.‚Äč

Figure 3: Confo Therapeutics’ proprietary Confobody platform.